Noom Real Customer Outcomes: What the Data Actually Shows

What Noom's Own Published Data Shows

Noom's most cited outcome study, published in Scientific Reports (2016), analyzed 35,921 app users over a median of 267 days. Of those users, 77.9% reported a net decrease in body weight from baseline [1]. The result is observational, not randomized, and drawn from users who voluntarily logged meals and weighed themselves. Self-selection bias is a real limitation here.

Average Weight Loss in the Cohort

Among participants who completed 6 months, the study reported average losses near 5% of starting body weight. Users who logged dinner more than 50% of the time lost significantly more weight than infrequent loggers [1]. A separate 2020 analysis in JMIR mHealth and uHealth of 36,000 Noom users over 15 months found that 64% achieved at least 5% body weight reduction [2]. Five percent is a clinically meaningful threshold. The American Heart Association and the Obesity Medicine Association both recognize that a 5%, 10% weight reduction can improve blood pressure, HbA1c, and lipid profiles [3].

How Logging Frequency Correlates With Outcomes

The data showed a clear dose-response relationship between engagement and results. Users who logged meals at least 66% of available days lost roughly twice as much weight as those who logged less than 33% of the time [1]. This pattern mirrors broader digital health research. A 2019 systematic review in Obesity Reviews found that self-monitoring frequency was the strongest predictor of weight loss across app-based interventions [4]. The question Noom's data cannot answer: would these highly engaged users have succeeded with any tracking tool?

How Noom Compares to Clinical Weight Loss Benchmarks

Behavioral interventions alone tend to produce 3%, 7% total body weight loss over 6 to 12 months, according to the U.S. Preventive Services Task Force [5]. Noom's published results sit squarely inside that range. That is not a criticism. It is context.

The Pharmacotherapy Gap

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo in the STEP-1 trial (N=1,961) [6]. Tirzepatide 15 mg (Zepbound) achieved 20.9% weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [7]. These numbers dwarf what any app-only program has demonstrated. The comparison is not entirely fair, because Noom was never designed to compete with injectable pharmacotherapy on magnitude of weight loss alone.

Behavioral Intervention Context

The Diabetes Prevention Program (DPP) trial, one of the most influential lifestyle-intervention studies ever conducted, showed 7% average weight loss with intensive counseling over 2.8 years [8]. Noom earned CDC recognition as a DPP-compatible digital program, which requires meeting specific outcome standards. Dr. Robert Kushner, a professor of medicine at Northwestern University's Feinberg School of Medicine, has noted that "digital tools that incorporate structured behavioral strategies can approximate the effect sizes of in-person lifestyle counseling when user engagement is sustained" [9].

Noom Med: The GLP-1 Prescribing Expansion

In 2023, Noom launched Noom Med, a telehealth prescribing service offering GLP-1 receptor agonists and other anti-obesity medications paired with Noom's behavioral coaching platform. This positions Noom in direct competition with dedicated weight loss telehealth services.

What Noom Med Prescribes

Through Noom Med, eligible patients may receive prescriptions for branded semaglutide (Wegovy), branded tirzepatide (Zepbound), or compounded alternatives depending on availability and insurance coverage. The prescribing is handled by licensed clinicians within Noom's telehealth network, not by the behavioral coaches [10]. Noom Med pricing starts around $49/month for the coaching component, with medication costs added separately. Branded GLP-1 medications run $800, $1,350/month without insurance.

Independent Evidence on the Combined Approach

No peer-reviewed, independently conducted randomized trial has yet evaluated Noom Med's combined coaching-plus-GLP-1 model against GLP-1 alone or against competing telehealth platforms. Noom has published internal pilot data suggesting higher medication adherence rates among users who also engage with the behavioral curriculum, but these results have not undergone independent peer review as of mid-2026.

The theoretical rationale is sound. The STEP-4 extension trial showed that patients who discontinued semaglutide after 20 weeks regained two-thirds of the weight they had lost within one year of stopping [11]. Behavioral support during and after pharmacotherapy could plausibly reduce regain. The 2024 American Association of Clinical Endocrinology (AACE) obesity guidelines recommend combining pharmacotherapy with structured lifestyle modification, stating that "multicomponent interventions including behavioral therapy, nutrition counseling, and physical activity guidance should accompany anti-obesity medication prescribing" [12].

Real User Patterns: What Reviews Reveal

Aggregated user review data from app stores and independent review platforms reveals consistent patterns, both positive and negative. These are not clinical endpoints, but they highlight the lived experience.

Common Positive Themes

Users frequently cite the "psychology-first" approach as a differentiator. Noom's curriculum draws on cognitive behavioral therapy (CBT) principles, teaching users to identify emotional eating triggers and reframe food-related thought patterns. The color-coded food categorization system (green, yellow, red/orange) is mentioned as intuitive by many users, though nutritionists have debated whether the simplified classification sometimes mislabels nutrient-dense foods like salmon or avocado as "red" due to caloric density alone [10].

Common Complaints

Three complaints recur across platforms. First, coaching quality varies. Noom uses group coaching rather than consistent 1-on-1 sessions with the same coach, and users report that responses can feel templated. Second, the subscription model creates friction. Users who forget to cancel before a trial ends are charged automatically, generating a high volume of billing complaints. Third, the calorie targets Noom assigns can be aggressively low. Some users report being given targets of 1,200 calories per day, which falls below the threshold that most clinical guidelines recommend without medical supervision [13].

Retention and Dropout Rates

Noom's own published data acknowledges significant dropout. In the 35,921-user study, the median observation period was 267 days, but many users dropped off well before that point [1]. A 2021 analysis in Obesity Science & Practice examining digital weight management programs broadly found that fewer than 50% of users remain active in app-based programs beyond 3 months [14]. Noom's engagement numbers are better than many competitors, but sustained long-term use remains the central challenge for all digital behavioral interventions.

Noom vs. Competing Platforms

The digital weight management space has expanded rapidly, with direct competitors now including WW (formerly Weight Watchers), Calibrate, Found, Ro Body, and dedicated GLP-1 telehealth platforms.

App-Only Comparisons

A 2022 randomized pilot published in JMIR mHealth and uHealth compared Noom to a standard calorie-tracking app over 12 weeks in 105 adults with overweight or obesity. Both groups lost weight, and the difference between groups was not statistically significant at the 12-week mark [15]. The study was small and short, but it raises a fair question about how much of the weight loss is attributable to Noom's specific curriculum versus the general act of self-monitoring.

WW's clinical evidence base is deeper. A 2015 meta-analysis in Annals of Internal Medicine across 39 trials found that WW participants lost 2.6% more body weight than control groups at 12 months [16]. WW has also launched its own GLP-1 clinical program. Head-to-head comparisons between Noom and WW with matched follow-up periods do not yet exist.

Telehealth GLP-1 Platform Comparisons

For users whose primary goal is GLP-1 access, dedicated telehealth platforms (Ro, Hims/Hers, Found, HealthRX) may offer more straightforward medication pathways. Noom Med bundles the behavioral app with prescribing, which adds cost if users do not engage with the coaching component. The value proposition depends on whether the user will actually use the behavioral modules. If they will, the combined model has clinical rationale. If they just want medication access, a standalone prescribing service may be more cost-efficient.

Who Is Noom Best Suited For?

Noom's strength is behavioral coaching delivered through a mobile interface. The platform works best for a specific user profile, and fails to meet expectations for others.

Good Fit Indicators

Users who are new to structured weight management, prefer learning why they eat rather than just what to eat, and respond to gamified app design tend to report the highest satisfaction. Noom is also a reasonable option for individuals who are 10 to 30 pounds from their goal weight and do not have clinical indications for pharmacotherapy. The CDC DPP recognition makes it a valid choice for prediabetes risk reduction specifically [8].

Poor Fit Indicators

Users with BMI >35 and obesity-related comorbidities may find that behavioral coaching alone produces insufficient weight loss. The AACE 2024 guidelines recommend pharmacotherapy as first-line for patients with BMI >30 (or BMI >27 with comorbidities), not behavioral intervention alone [12]. Users seeking consistent 1-on-1 coaching from a single provider will likely be disappointed by Noom's group-based model. And users who are price-sensitive should calculate total costs carefully. A 12-month Noom subscription at $42, $70/month costs $504, $840/year before any medication costs through Noom Med.

The Bottom Line on Noom's Evidence

Noom has more published outcome data than most digital weight loss apps. That is a low bar. The 35,921-user observational study [1] and the 15-month longitudinal analysis [2] are legitimate data points, but both lack randomized controls and rely on self-selected, engaged users. The weight loss magnitudes reported (3%, 5% of body weight) are consistent with behavioral intervention benchmarks but substantially below what GLP-1 pharmacotherapy achieves.

Noom Med's entry into prescribing adds clinical weight, though independent validation is still needed. The combination of behavioral coaching and GLP-1 medication aligns with current AACE and Endocrine Society recommendations for multimodal obesity treatment [12]. Whether Noom's specific behavioral platform adds measurable value beyond what any structured support would provide remains an open empirical question.

For patients currently weighing pharmacotherapy, a baseline metabolic panel, HbA1c, and lipid panel should precede any prescribing decision, whether through Noom Med or another provider [12].